TITLE

THE SINGLE DOSE METHOD OF ADMINISTERING CHOLESTYRAMINE

AUTHOR(S)
Casdorph, H. Richard
PUB. DATE
October 1975
SOURCE
Angiology;Oct1975, Vol. 26 Issue 9, p671
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Looks into the use of cholestyramine for treatment of type II hyperlipoproteinemia. Evaluation of the efficacy of administering cholestyramine to patients; Determination of triglycerides at less frequent intervals; Number of patients examined for the study.
ACCESSION #
16352102

 

Related Articles

  • Primary Type V Hyperlipoproteinemia. Greenberg, Barry H.; Blackwelder, William C.; Levy, Robert I. // Annals of Internal Medicine;Nov77, Vol. 87 Issue 5, p526 

    Presents information on a study which described the clinical and biochemical characteristics of kindreds that were identified through propositi with primary type V hyperlipoproteinemia Methods; Results; Discussion.

  • Management of Type IV Hyperlipoproteinemia. Smith, L. Kent; Luepker, Russell V.; Rothchild, Sarah S.; Gillis, Albert; Kochman, Leon; Warbasse, J. Richard // Annals of Internal Medicine;Jan76, Vol. 84 Issue 1, p22 

    Presents a study which examined the clinical approaches for the management of type IV hyperlipoproteinemia. Association of lipoprotein diseases, particulary type IV hyperlipoproteinemia with atherosclerotic disease; Methods; Results and discussion.

  • Hyperlipoproteinemia: Problems in Diagnosis and Challenges Posed by the "Type III" Disorder.  // Annals of Internal Medicine;Feb75, Vol. 82 Issue 2, p273 

    Editorial. Presents an article on the examination of the incidence of type III hyperlipoproteinemia. Information on the electrophoresis of lipoproteins in relation to the disease; Description of patients with the disease.

  • Nutritional & Pharmacologic Management of Hyperlipoproteinemia. Edward Pickering, J. // Angiology;Sep1982, Vol. 33 Issue 9, p577 

    The results of the nutritional intervention on one of the twenty MRFIT centers is presented. The reduction in cholesterol was 5.78% after four years. Those results were compared with the changes found in serum cholesterol with a similar diet and the administration of either clofibrate or...

  • Cholestyramine in Type II Hyperlipoproteinemia. Levy, R.I.; Frederickson, D.S.; Stone, N.J.; Bilheimer, D.W.; Brown, W.V.; Glueck, C.J.; Gotto, A.M.; Herbert, P.N.; Kwiterovich, P.O.; Langer, T.; LaRosa, J.; Lux, S.E.; Rider, A.K.; Schulman, R.S.; Sloan, H.R. // Annals of Internal Medicine;Jul73, Vol. 79 Issue 1, p51 

    Presents a study which examined the efficacy of chlorestyramine in the treatment of type II hyperlipoproteinemia. Patients and methods; Results; Discussion.

  • Hyperlipoproteinemia.  // Diseases & Disorders: A Nursing Therapeutics Manual, 2nd edition;2002, p471 

    Provides information on hyperlipoproteinemia, a condition characterized by increased lipids in the blood that causes decreased rate of lipoprotein breakdown. Types of hyperlipoproteinemia; Causes of hyperlipoproteinemia; Diagnosis and clinical management of hyperlipoproteinemia.

  • Incidence dyslipidemií v populaci dÄ›tí s obezitou. Pastucha, D.; Hyjánek, J.; Malinčíková, J. // Czecho-Slovak Pediatrics / Cesko-Slovenska Pediatrie;Mar2012, Vol. 67 Issue 3, p147 

    The incidence of occurrence of individual forms of dyslipidemia in described in 182 obese children followed in a children obesitology outpatient at the Clinic of Physical Education and Cardiovascular Rehabilitation at Faculty Hospital Olomouc. It has become obvious that in our cohort of child...

  • STUDY OF DYSLIPIDEMIA IN POSTMENOPAUSE WITH SPECIAL REFERENCE TO SERUM BUTYRYLCHOLINESTERASE AND LIPOPROTEIN (a) [Lp (a)]. Umeshchandra, Suman; Umeshchandra, D. G.; Awanti, S. M. // International Journal of Pharmaceutical Sciences Review & Resear;Jan/Feb2012, Vol. 12 Issue 1, p123 

    Hyperlipidaemia is one of the important risk factor for the development of coronary heart disease. Butyrylcholinesterase is a serum esterase which is synthesized primarily in the liver, increased serum butyrylcholinesterase activity is found to be associated with altered lipid metabolism such as...

  • A Comparative Study of Lipid Profile In Hospitalized Patients. Anand, Jitendraa; Joshi, Anant // JK Science;Jan-Mar2015, Vol. 17 Issue 1, p22 

    Dyslipidaemia is a major risk factor for the development of cardiovascular disease. Present study, was aimed to find out the lipid profile in hospitalized patients. The mean ± SD (mg/dl) level of total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL) and high density...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics